
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
JAGUAR HEALTH 25 DL-,0001 1JA0 US47010C8881 BAW/UFN
© 2025 Xetra Newsboard
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Do | Jaguar Health, Inc.: Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs | Company's Canalevia®-CA1 (crofelemer delayed-release tablets) prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment... ► Artikel lesen | |
Mi | Jaguar Health, Inc.: Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts | Crofelemer is the only oral drug approved by the FDA's Center for Drug Evaluation and Research under Botanical GuidanceClick here to access replay of company's April 30, 2025 investor webcast SAN FRANCISCO... ► Artikel lesen | |
30.04. | Jaguar Health meldet vielversprechende Ergebnisse für Crofelemer bei seltenen Krankheiten | ||
30.04. | Jaguar Health, Inc.: Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease and Short Bowel Syndrome with Intestinal Failure by up to 27% and 12.5% - Potential to Modify Dis | Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the proof-of-concept study of crofelemer for MVID and SBS-IF presented April 26 at the Annual ELITE PED-GI... ► Artikel lesen | |
29.04. | Jaguar Health, Inc.: REMINDER: Jaguar Health Hosting April 30 Investor Webcast to Present Initial Results from Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease and Short Bowel Syndrome with Intestinal Failure | The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for... ► Artikel lesen |